Intellia Therapeutics Announces First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Intellia Therapeutics (NTLA) Misses Q1 EPS by 19c, Revenues Miss
May 7, 2020 7:44 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.63), $0.19 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.92 million versus the consensus estimate of $18.14 million.
At Intellia, our mission is to develop curative, CRISPR/Cas9-based treatments for severe diseases. I am... More
